GSK’s Asthma Drug Meets Primary Endpoint in Phase 3 Trial

September 10, 2024

Sage Anticipates Job Cuts and Project Scaling Down Following Zuranolone’s MDD Rejection

August 7, 2023

Good News For Enterprise As It Announces Phase 2 Cystic Fibrosis Victory

May 19, 2026

Must Read

Lilly challenges J&J in the market for psychedelic mental health by paying $2.8 billion up front for AtaiBeckley

July 31, 2026

The Next Wave of Innovation in Oncology

July 31, 2026

GSK will increase its R&D efforts by investing £400 million in Britain over three years

July 30, 2026

About Us

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

Summit and Akeso Report Updated HARMONi Survival Data for Ivonescimab in Western NSCLC Patients

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

Biogen’s Phase 2 Diranersen Data Shows Reduced Cognitive Decline in Alzheimer’s Disease

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

Hansoh Announces Fresh Phase 3 Victory For Priority ADC

Altimmune Reports Phase 2 Pemvidutide Results in Alcohol Use Disorder

Sanofi Ends Amlitelimab Development in Atopic Dermatitis After Phase 3 Program Review

J&J’s Bispecific Combination Works Wonders on Myeloma Progression in Phase 3 Study

Lilly challenges J&J in the market for psychedelic mental health by paying $2.8 billion up front for AtaiBeckley

GSK will increase its R&D efforts by investing £400 million in Britain over three years

Included Health Agrees to Acquire Firefly Health to Expand Employer Health Plan Alternatives

J&J’s OTTAV Robotic Surgical System has received FDA market authorization in the U.S.

Alnylam Inks $2B Agreement With Inceptive to Change sIRNA Design With AI Leader

Chugai and Gero Partner to Develop Antibodies for Age-Related Diseases Using AI

J&J MedTech presents the first Ottava surgical robot clinical cases

The Next Wave of Innovation in Oncology

The Workforce Challenge Facing Biopharma Manufacturing

What Pharma Leaders Are Prioritizing in 2026

How RNA Therapeutics Are Expanding Beyond Rare Diseases

Tag: Sanofi

With the best pipeline in the industry, Lilly’s stock and valuation soar in 2021

Editor Picks

GSK’s Asthma Drug Meets Primary Endpoint in Phase 3 Trial

Sage Anticipates Job Cuts and Project Scaling Down Following Zuranolone’s MDD Rejection

Good News For Enterprise As It Announces Phase 2 Cystic Fibrosis Victory

Must Read

Lilly challenges J&J in the market for psychedelic mental health by paying $2.8 billion up front for AtaiBeckley

The Next Wave of Innovation in Oncology

GSK will increase its R&D efforts by investing £400 million in Britain over three years

Hot Topics

About Us

Follow Us